Countering Lung Damage in COVID-19 infection (CounterCovid) study

Amsterdam UMC0 个研究点目标入组 386 人开始时间: 待定最近更新: 2024年2月28日

试验速览

暂无简介。

•1. Pre-existing chronic pulmonary disease, including:
•? Known diagnosis of Interstitial Lung disease
•? Former diagnosis of COPD 4 or FEV1<30%pred
•? DLCO <45%
•? Total lung capacity (TLC) < 60% of predicted
•? Lung cancer with non-surgical treatment in last year
•2. Home oxygen treatment
•3. Pre-existing heart failure with a known left ventricular ejection fraction <40%
•4. Active treatment of hematological or non-hematological cancer with targeted, immuno- or chemotherapy in the last year
•4. Inability to provide informed consent
•5. Any subject who had received any investigational medication within 1 month prior to the start of this study or who is scheduled to receive another investigational drug during the course of this study
•6. Active liver disease, porphyria or elevations of serums transaminases >3 x ULN (upper limit of normal) or bilirubin > 1.5 x ULN
•7. History or suspicion of inability to cooperate adequately.
•8. White blood count < 4.0^109/l
•9. Hemoglobin < 6.0 mmol/l
•10. Thrombocytes < 100^109/l
•11. Pregnant female subjects
•12. Breastfeeding female subjects

发起方

Amsterdam UMC